Table 2.
Efficacy metrics from most recent publicly reported data in key response-evaluable populations
| Response | CLL/SLL, n = 276 (previous cBTKi)1 | MCL, n = 90 (previous cBTKi)2 | RT, n = 753 | WM (previous cBTKi),4 n = 55 |
|---|---|---|---|---|
| ORR/major response (for WM) | 74 | 57.8 | 52.0 | 64 |
| VGPR (WM)/CR (others) | 1 | 20.0 | 13.3 | 24 |
| PR | 64 | 37.8 | 38.7 | 40 |
| PR-L (CLL)/minor response (WM) | 8 | N/A | N/A | Not reported |
| SD | Not reported | 15.6 | 13.3 | Not reported |
| Median DOR (mo) | Not reported | 22 | 5.6 | 83% at 6 mo |
| Median PFS (mo) | 19.4 | 7.4 | 3.7 | Not reported |
| Median OS (mo) | NE | NE | 13.1 | NE |
CR, complete remission; N/A, not available; NE, not estimable; PR, partial remission; PR-L, partial remission with lymphocytosis; SD, stable disease; VGPR, very good partial remission.